Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 9/2017

01-09-2017 | Review

Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine

Authors: Vitaly A. Kushnir, David B. Seifer, David H. Barad, Aritro Sen, Norbert Gleicher

Published in: Journal of Assisted Reproduction and Genetics | Issue 9/2017

Login to get access

Abstract

Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.
Literature
1.
Seifer DB, Tal R. Antimullerian hormone: biology, role in ovarian function and clinical significance. New York: Nova Science Publishers; 2016.
2.
Laurich VM, Trbovich AM, O’Neill FH, Houk CP, Sluss PM, Payne AH, et al. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p 450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. Endocrinology. 2002;143(9):3351–60.CrossRefPubMed
3.
Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum Reprod Update. 2005;11(4):351–6.CrossRefPubMed
4.
Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076–84.CrossRefPubMed
5.
Ueno S, Manganaro TF, Donahoe PK. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology. 1988;123(3):1652–9.CrossRefPubMed
6.
Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA, et al. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J Clin Endocrinol Metab. 1992;75(3):911–7.PubMed
7.
Kedem A, Yung Y, Yerushalmi GM, Haas J, Maman E, Hanochi M, et al. Anti Müllerian hormone (AMH) level and expression in mural and cumulus cells in relation to age. J Ovarian Res. 2014;7:113.CrossRefPubMedPubMedCentral
8.
Kedem A, Hourvitz A, Yung Y, Shalev L, Yerushalmi GM, Kanety H, et al. Anti-Müllerian hormone (AMH) downregulation in late antral stages is impaired in PCOS patients. A study in normo-ovulatory and PCOS patients undergoing in vitro maturation (IVM) treatments. Gynecol Endocrinol. 2013;29(7):651–6.CrossRefPubMed
9.
Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, et al. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A. 2002;99(1):239–44.CrossRefPubMedPubMedCentral
10.
Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, et al. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem. 2001;276(29):26799–806.CrossRefPubMed
11.
Wang J, Dicken C, Lustbader JW, Tortoriello DV. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Fertil Steril. 2009;91(4):1195–203.CrossRefPubMed
12.
Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055.CrossRefPubMedPubMedCentral
13.
14.
Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, et al. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content. J Clin Endocrinol Metab. 1993;76(3):711–4.PubMed
15.
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77(3):468–71.CrossRefPubMed
16.
Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1999;84(8):2696–9.PubMed
17.
Bry-Gauillard H, Larrat-Ledoux F, Levaillant JM, Massin N, Maione L, Beau I, et al. Anti-Mullerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism/Kallmann syndrome. Effects of recombinant human FSH. J Clin Endocrinol Metab. 2017
18.
La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol. 2006;64(6):603–10.CrossRef
19.
Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.CrossRefPubMedPubMedCentral
20.
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015;103(1):119–30.e3.CrossRefPubMed
21.
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59.e1–8.CrossRef
22.
Gleicher N, Darmon SK, Kushnir VA, Weghofer A, Wang Q, Zhang L, et al. How FSH and AMH reflect probabilities of oocyte numbers in poor prognosis patients with small oocyte yields. Endocrine. 2016;54(2):476–83.CrossRefPubMed
23.
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;21.
24.
Nyboe Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107(2):387–396.e4.CrossRefPubMed
25.
Matias-Guiu X, Pons C, Prat J. Müllerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29(8):840–5.CrossRefPubMed
26.
Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP, et al. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol. 2000;31(10):1202–8.CrossRefPubMed
27.
Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, et al. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst. 2009;101(21):1501–9.CrossRefPubMedPubMedCentral
28.
Nichols HB, Baird DD, Stanczyk FZ, Steiner AZ, Troester MA, Whitworth KW, et al. Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk. Cancer Prev Res (Phila). 2015;8(6):528–34.CrossRef
29.
Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-Müllerian hormone concentrations and risk of breast cancer among premenopausal women in the nurses’ health studies. Cancer Epidemiol Biomark Prev. 2016;25(5):854–60.CrossRef
30.
Teixeira J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev. 2001;22(5):657–74.PubMed
31.
MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol. 2010;6(3):391–405.CrossRefPubMedPubMedCentral
32.
Kim JH, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: a novel treatment for gynecologic tumors. Obstet Gynecol Sci. 2014;57(5):343–57.CrossRefPubMedPubMedCentral
33.
Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999;140(12):5789–96.CrossRefPubMed
34.
Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223–7.CrossRefPubMed
35.
Hayes E, Kushnir V, Ma X, Biswas A, Prizant H, Gleicher N, et al. Intra-cellular mechanism of anti-Müllerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol. 2016;433:56–65.CrossRefPubMed
36.
Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci U S A. 2017;114(9):E1688–97.CrossRefPubMedPubMedCentral
37.
Margolskee A, Selgrade JF. A lifelong model for the female reproductive cycle with an antimüllerian hormone treatment to delay menopause. J Theor Biol. 2013;326:21–35.CrossRefPubMed
38.
Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004;19(9):2036–42.CrossRefPubMed
39.
Tehrani FR, Solaymani-Dodaran M, Hedayati M, Azizi F. Is polycystic ovary syndrome an exception for reproductive aging? Hum Reprod. 2010;25(7):1775–81.CrossRefPubMed
40.
Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62.CrossRefPubMed
41.
Goldman KN, Chenette D, Arju R, Duncan FE, Keefe DL, Grifo JA, et al. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. Proc Natl Acad Sci U S A. 2017;114(12):3186–91.CrossRefPubMed
42.
43.
Kushnir VA, Safdie M, Darmon SK, Albertini DF, Barad DH, Gleicher N. Age-specific IVF outcomes in infertile women with baseline FSH levels ≥20 mIU/mL. Reprod Sci. 2017;1:1933719117697130.
44.
Gleicher N, Kushnir VA, Sen A, Darmon SK, Weghofer A, Wu Y, et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med. 2016;14(1).
45.
Gleicher N, Vega MV, Darmon SK, Weghofer A, Wu YG, Wang Q, et al. Live-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transfered. Fertil Steril. 2015.
46.
Nassar J, Tadros T, Adda-Herzog E, Ayoubi JM, Fanchin R. Steroid hormone pretreatments in assisted reproductive technology. Fertil Steril. 2016;106(7):1608–14.CrossRefPubMed
47.
Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29(6):684–91.CrossRefPubMed
48.
Wu YG, Barad DH, Kushnir VA, Lazzaroni E, Wang Q, Albertini DF, et al. Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval. J Endocrinol. 2015;226(3):167–80.CrossRefPubMed
49.
Gleicher N, Kushnir VA, Albertini DF, Barad DH. Improvements in IVF in women of advanced age. J Endocrinol. 2016;230(1):F1–6.CrossRefPubMed
50.
Gleicher N, Kushnir VA, Barad DH. Therapeutic interventions into early stages of follicle maturation: a new treatment paradigm after over 50 years of modern infertility therapy. Endocrinology. 2013;154(10):3498–501.CrossRefPubMed
51.
Carrarelli P, Rocha AL, Belmonte G, Zupi E, Abrão MS, Arcuri F, et al. Increased expression of antimüllerian hormone and its receptor in endometriosis. Fertil Steril. 2014;101(5):1353–8.CrossRefPubMed
52.
Borahay MA, Lu F, Ozpolat B, Tekedereli I, Gurates B, Karipcin S, et al. Mullerian inhibiting substance suppresses proliferation and induces apoptosis and autophagy in endometriosis cells in vitro. ISRN Obstet Gynecol. 2013;2013:361489.PubMedPubMedCentral
53.
Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, et al. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab. 2012;97(9):3224–30.CrossRefPubMed
54.
Signorile PG, Petraglia F, Baldi A. Anti-mullerian hormone is expressed by endometriosis tissues and induces cell cycle arrest and apoptosis in endometriosis cells. J Exp Clin Cancer Res. 2014;33:46.CrossRefPubMedPubMedCentral
55.
La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004;82(4):970–2.CrossRefPubMed
56.
Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296(2):E238–43.CrossRefPubMed
57.
Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24(11):2917–23.CrossRefPubMed
58.
Lin YH, Chiu WC, Wu CH, Tzeng CR, Hsu CS, Hsu MI. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril. 2011;96(1):230–5.CrossRefPubMed
59.
Sjaarda LA, Mumford SL, Kissell K, Schliep KC, Hammoud AO, Perkins NJ, et al. Increased androgen, anti-Müllerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype? J Clin Endocrinol Metab. 2014;99(6):2208–16.CrossRefPubMedPubMedCentral
60.
Kushnir VA, Halevy N, Barad DH, Albertini DF, Gleicher N. Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome. J Ovarian Res. 2015;8(1):45.CrossRefPubMedPubMedCentral
61.
Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941–5.CrossRefPubMed
62.
Albertini DF. The mammalian oocyte. In: Plant TM, Zeleznik AJ, editors. Knobil and Neill’s Physiology of reproduction. 4, revised. Academic Press; 2014.
63.
64.
Gleicher N, Kushnir VA, Darmon SK, Wang Q, Zhang L, Albertini DF, et al. New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens. J Steroid Biochem Mol Biol. 2016.
65.
Gleicher N, Kim A, Weghofer A, Kushnir VA, Shohat-Tal A, Lazzaroni E, et al. Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod. 2013;28(4):1084–91.CrossRefPubMed
66.
Gleicher N, Kushnir VA, Weghofer A, Barad DH. The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod Biol Endocrinol. 2016;14:23.CrossRefPubMedPubMedCentral
67.
Shohat-Tal A, Sen A, Barad DH, Kushnir V, Gleicher N. Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat Rev Endocrinol. 2015;11(7):429–41.CrossRefPubMed
68.
Sen A, Kushnir VA, Barad DH, Gleicher N. Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol. 2014;10(1):37–50.CrossRefPubMed
69.
Keegan CE, Hammer GD. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab. 2002;13(5):200–8.CrossRefPubMed
70.
Kong HS, Kim SK, Lee J, Youm HW, Lee JR, Suh CS, et al. Effect of exogenous anti-Müllerian hormone treatment on cryopreserved and transplanted mouse ovaries. Reprod Sci. 2016;23(1):51–60.CrossRefPubMed
71.
Meirow D, Roness H, Kristensen SG, Andersen CY. Optimizing outcomes from ovarian tissue cryopreservation and transplantation; activation versus preservation. Hum Reprod. 2015;30(11):2453–6.CrossRefPubMed
72.
Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013;110(43):17474–9.CrossRefPubMedPubMedCentral
73.
Novella-Maestre E, Herraiz S, Rodríguez-Iglesias B, Díaz-García C, Pellicer A. Short-term PTEN inhibition improves in vitro activation of primordial follicles, preserves follicular viability, and restores AMH levels in cryopreserved ovarian tissue from cancer patients. PLoS One. 2015;10(5):e0127786.CrossRefPubMedPubMedCentral
74.
Telfer EE, McLaughlin M. Strategies to support human oocyte development in vitro. Int J Dev Biol. 2012;56(10–12):901–7.CrossRefPubMed
75.
76.
Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 2010;19(1):77–91.CrossRefPubMed
77.
78.
Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, et al. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol. 2008;108(1):141–8.CrossRefPubMed
79.
Kersual N, Garambois V, Chardès T, Pouget JP, Salhi I, Bascoul-Mollevi C, et al. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. MAbs. 2014;6(5):1314–26.CrossRefPubMedPubMedCentral
80.
Donahoe PK, Swann DA, Hayashi A, Sullivan MD. Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science. 1979;205(4409):913–5.CrossRefPubMed
81.
La Marca A, Volpe A. The anti-Mullerian hormone and ovarian cancer. Hum Reprod Update. 2007;13(3):265–73.CrossRefPubMed
82.
Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 2006;12(5):1593–8.CrossRefPubMed
83.
Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 1999;5(11):3488–99.PubMed
84.
Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2005;102(1):111–6.CrossRefPubMed
85.
Song JY, Jo HH, Kim MR, Lew YO, Ryu KS, Cha JH, et al. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. Int J Oncol. 2012;40(6):2013–21.PubMed
86.
Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003;100(26):15601–6.CrossRefPubMedPubMedCentral
87.
Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, et al. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem. 2000;275(37):28371–9.CrossRefPubMed
88.
Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, et al. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Cancer Res. 2007;67(6):2747–56.CrossRefPubMed
89.
Rodina AV, Gukasova NV, Makarov VA, Kondrasheva IG, Khomyakova AV, Posypanova GA, et al. Localization of Mullerian inhibiting substance receptors in various human cancer cell lines. Biochem Mosc. 2008;73(7):797–805.CrossRef
90.
Tran TT, Segev DL, Gupta V, Kawakubo H, Yeo G, Donahoe PK, et al. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism. Mol Endocrinol. 2006;20(10):2382–91.CrossRefPubMed
91.
Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM, Donahoe PK. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Res. 1992;52(5):1182–6.PubMed
92.
Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif. 1992;3(3):236–45.CrossRefPubMed
93.
Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT. New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;766(1):89–98.CrossRefPubMed
94.
Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X, et al. Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian inhibiting substance. Protein Expr Purif. 2010;70(1):32–8.CrossRefPubMed
95.
Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Factories. 2009;8:17.CrossRef
96.
Ma JK, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 2003;4(10):794–805.CrossRefPubMed
Metadata
Title
Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine
Authors
Vitaly A. Kushnir
David B. Seifer
David H. Barad
Aritro Sen
Norbert Gleicher
Publication date
01-09-2017
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 9/2017
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-017-0977-4

Other articles of this Issue 9/2017

Journal of Assisted Reproduction and Genetics 9/2017 Go to the issue

Assisted Reproduction Technologies

Anti-Mullerian hormone concentrations in individual follicular fluids within one stimulated IVF cycle resemble blood serum values

Assisted Reproduction Technologies

Ovarian hyperstimulation syndrome following GnRH agonist trigger—think ectopic

Gamete Biology

Obesity results with smaller oocyte in in vitro fertilization/intracytoplasmic sperm injection cycles—a prospective study

Reproductive Physiology and Disease

The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro

Fertility Preservation

Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation

Assisted Reproduction Technologies

National survey on use of time-lapse imaging systems in IVF laboratories